Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064358 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT05064358: Active Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
NCT05064358 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 177 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05064358, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Primary Outcome
The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with s
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
Study Locations (20)
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Capital Federal
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
- GSK Investigational Site - Pilar
- GSK Investigational Site - Rosario
- GSK Investigational Site - Joinville
- GSK Investigational Site - Porto Alegre
- GSK Investigational Site - Rio de Janeiro
- GSK Investigational Site - Salvador
- GSK Investigational Site - São Paulo
Tennessee
- GSK Investigational Site - Chattanooga
- GSK Investigational Site - Nashville
New South Wales
- GSK Investigational Site - Liverpool
- GSK Investigational Site - Newcastle
Florida
- GSK Investigational Site - West Palm Beach
Missouri
- GSK Investigational Site - Kansas City
New York
- GSK Investigational Site - New York
Texas
- GSK Investigational Site - Houston
South Australia
- GSK Investigational Site - Woodville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
What the registry record for NCT05064358 still lists
NCT05064358 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Belantamab mafodotin is the first listed.
NCT05064358 names 20 study sites across 9 states, led by Other, Tennessee, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05064358 about?
NCT05064358 is a clinical study titled "Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma". This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
What is the current status of trial NCT05064358?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2022-03-03. Estimated completion is 2026-01-30.
What conditions does trial NCT05064358 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05064358?
The interventions under investigation include: Belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT05064358?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064358 being conducted?
This trial has 20 study locations across Florida, Missouri, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05064358's enrollment target sits among peer trials
177 122nd of 438 higher than 316 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI